EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

Aymara Sancho-Araiz iD, Zinnia P Parra-Guillen iD, Iñaki F Troconiz iD, Tomoko Freshwater

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Aymara Sancho-Araiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Science, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Oncolytic Viruses, Oncolytic Virotherapy, Immunotherapy. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immuno‐oncology (IO) is a growing strategy in cancer treatment. Oncolytic viruses (OVs) can selectively infect cancer cells and lead to direct and/or immune‐dependent tumor lysis. This approach represents an opportunity to potentiate the efficacy of immune checkpoint inhibitors (ICI), such as pembrolizumab. Currently, there is a lack of comprehensive quantitative models for the aforementioned scenarios. In this work, we developed a mechanistic framework describing viral kinetics, viral dynamics, and tumor response after intratumoral (i.t.) or intravenous (i.v.) administration of V937 alone or in combination with pembrolizumab. The model accounts for tumor shrinkage, in both injected and non‐injected lesions, induced by: viral‐infected tumor cell death and activated CD8 cells. OV‐infected tumor cells enhanced the expansion of CD8 cells, whereas pembrolizumab inhibits their exhaustion by competing with PD‐L1 in their binding to PD‐1. Circulating viral levels and treatment effects on tumor volume were adequately characterized in all the different scenarios. This mechanistic‐based model has been developed by combining top‐down and bottom‐up approaches and provides individual estimates of viral and ICI responses. The robustness of the model is reflected by the description of the tumor size time profiles in a variety of clinical scenarios. Additionally, this platform allows us to investigate not only the contribution of processes related to the viral kinetics and dynamics on tumor response, but also the influence of its interaction with an ICI. Additionally, the model can be used to explore different scenarios aiming to optimize treatment combinations and support clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedOncolytic VirusesOncolytic VirotherapyImmunotherapyHumansCD8-Positive T-LymphocytesNeoplasmsAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsCombined Modality TherapyModels, Biological

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Science, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Institute of Data Science and Artificial Intelligence, DATAI, University of Navarra, Pamplona, Spain.
  • Oncology Early Development, Clinical Research, Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Aymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz

Zitieren

APA

Sancho-Araiz, A., Parra-Guillen, Z. P., Troconiz, I. F., & Freshwater, T. (2024). Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3379

Vancouver

Sancho-Araiz A, Parra-Guillen ZP, Troconiz IF, Freshwater T. Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3379

BibTeX
@article{SanchoAraiz2024,
  author = {Sancho-Araiz, Aymara and Parra-Guillen, Zinnia P and Troconiz, Iñaki F and Freshwater, Tomoko},
  title = {Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3379}
}
Kostenlos starten →